|
Resolution: standard / high Figure 1.
Metabolic reprogramming in tumor cells. The alteration of bioenergetic pathways in
tumor cells is evident from their increased glucose uptake (a) through glycolysis (b), the intermediate metabolites of which are also shuttled into biosynthetic pathways
(synthesis of nucleic acids from glucose 6-phosphate through the pentose phosphate
pathway (c), amino acids from glycerate 3-phosphate (not shown) and lipogenesis from pyruvate
(d)) that are necessary for cell growth and proliferation. In tumor cells, pyruvate in
the mitochondria is shuttled into a truncated tricarboxylic acid cycle where it is
converted to acetyl-CoA by pyruvate dehydrogenase and combined with oxaloacetate for
export into the cytosol as citrate for the synthesis of isoprenoids, cholesterol and
fatty acids. Open up and down arrows indicate upregulation and downregulation of enzymes,
respectively. Enzymes upregulated by activation of HIF-1 are in red. Abbreviations:
ACL, adenosine triphosphate citrate lyase; ADP, adenosine diphosphate; ATP, adenosine
triphosphate; CA9 and CA12, carbonic anhydrases 9 and 12; CPT1A, carnitine palmitoyltransferase
1A; FASN, fatty acid synthase; G6P, glucose 6-phosphate; GLUT1,3,4, glucose transporter
1, 3 and 4; GSH, glutathione; HIF-1, hypoxia-inducible factor 1; HK1,2, hexokinase1
and 2; LAT1, L-type amino acid transporter 1; LDH-A, lactate dehydrogenase A; MCT4,
monocarboxylate transporter 4; M2-PK, pyruvate kinase isoform M2; NAD+, nicotinamide adenine dinucleotide oxidized; NADH, nicotinamide adenine dinucleotide
reduced; NADPH, nicotinamide adenine dinucleotide phosphate; NHE1, Na+/H+ exchanger 1; OAA, oxaloacetate; OXPHOS, oxidative phosphorylation; PDH, pyruvate dehydrogenase;
PDK1, pyruvate dehydrogenase kinase 1; PFK2, phosphofructokinase 2; PGM, phosphoglycerate
mutase; PI3K, phosphatidylinositol 3-kinase; PPP, pentose phosphate pathway; TLK1,
transketolase 1; VDAC, voltage-dependent anion channel. Reproduced with permission
from [2].
Van and Veenstra Genome Medicine 2009 1:5 doi:10.1186/gm5 |